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Cognitive decline and disease progression in different neurodegenerative diseases typically involves synaptic
dysfunction preceding the neuronal loss. The synaptic dysfunction is suggested to be caused by imbalanced
synaptic plasticity i.e. enhanced induction of long-term depression and concomitantly decreased long-term
potentiation accompanied with excess stimulation of extrasynaptic N-Methyl-D-aspartate (NMDA) receptors
due to various disturbances in pre- and postsynaptic sites. Recent research has identified neurodegenerative
disease-related changes in protein accumulation and aggregation, gene expression, and protein functions, which
may contribute to imbalanced synaptic function. Nevertheless, a comprehensive understanding of the mechanisms
regulating synaptic plasticity in health and disease is still lacking and therefore characterization of new candidates
involved in these mechanisms is needed. Septins, a highly conserved group of guanosine-5'-triphosphate
(GTP)-binding proteins, show high neuronal expression and are implicated in the regulation of synaptic vesicle
trafficking and neurotransmitter release. In this review, we first summarize the evidence how synaptic dysfunction is
related to the pathogenesis of Alzheimer’s, Parkinson’s and Huntington’s disease and frontotemporal lobar degeneration.
Then, we discuss different aspects of the potential involvement of the septin family members in the regulation of
synaptic function in relation to the pathogenesis of neurodegenerative diseases.
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Impaired function and degeneration of synapses are
among the earliest pathological alterations in neurode-
generative diseases. The exact molecular mechanisms that
cause synaptic dysfunction in neurodegenerative diseases
remain unclear, but significant efforts have been invested
on understanding disease-related alterations in synaptic
structure, function, and plasticity. Synaptic plasticity is
generally divided into two main forms, long-term poten-
tiation (LTP) and long-term depression (LTD). LTP is a
process linked to learning and memory formation. In LTP,
coinciding activation of both pre- and postsynaptic ele-
ments take place, leading to a long-lasting increase in syn-
aptic transmission between the terminals and persistent* Correspondence: mikko.hiltunen@uef.fi
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unless otherwise stated.strengthening of the synapse [1]. LTD, in turn, is a process
depressing synaptic activity for a prolonged time. It is
believed that in several neurodegenerative disorders,
LTP is disrupted and LTD is promoted [2-4]. The most
prominent forms of LTP and LTD are N-Methyl-D-as-
partate receptor (NMDAR)-dependent. Different patterns
of synaptic activation result in NMDAR activation, leading
to induction of either LTP or LTD, through regulation
of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptor (AMPAR) localization at the postsynaptic ter-
minal [5,6]. Overstimulation of extrasynaptic NMDAR is
commonly noticed in neurological disorders, leading to an
excess influx of calcium to the postsynaptic site, possibly
promoting LTD and triggering various neurodegenerative
events [7-9]. Also, observed variations in presynaptic
and astrocyte activity have supported the idea for
disease-related extrasynaptic NMDAR activation and
LTP suppression [10,11]. Studying the relation between
neurodegenerative disorders and alterations in synaptic
plasticity is difficult due to that fact that the underlyingral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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results in LTP or LTD, are not completely understood [6].
In addition, the neurodegenerative disease-associated me-
chanisms affecting the formation of LTP or LTD are thus
far not clear. However, recent studies have identified sev-
eral factors involved in neurodegenerative disorders,
which may modulate synaptic plasticity, Although the
understanding of synaptic function-related processes
has recently leaped forward, unraveling the detailed
mechanisms of synaptic function is essential for un-
derstanding the pathogenesis of neurodegenerative dis-
eases at the molecular level. Recent studies have identified
septin protein family members as possible candidates that
take part in the regulation of synaptic processes and
whose altered function might be involved in synaptic dys-
function in neurodegenerative diseases. Septins belong to
a highly conserved family of guanosine-5'-triphosphate
(GTP)-binding proteins, which play a role in the axonal
transport, vesicular trafficking, and neurotransmitter re-
lease [10,12]. In addition, septins have been shown to
interact with several key components related to neuro-
logical disorders (e.g. CDK5, XIAP/caspase-3, VAMP2,
Parkin, and EAAT1). In this review, we will provide
insights into synaptic dysfunction in neurodegenerative
diseases, and how septins could play a role in the events
leading to impaired synaptic function.
Synaptic dysfunction in Alzheimer’s disease
Alzheimer’s disease (AD) is the most common neuro-
degenerative disorder in the world, which affects up to
50% of individuals above the age of 85. AD is clinically
associated with a global cognitive decline and progres-
sive loss of memory and reasoning. At autopsy, a large
number of neuritic plaques and neurofibrillary tangles
(NFT) in the neocortex of the brain are detected. These
consist of amyloid-β (Aβ) peptide and hyperphosphory-
lated tau protein, respectively [13-16]. The Aβ peptide is
released from APP after sequential proteolytic cleavage
by β- and γ-secretases. The majority of APP is cleaved
by α-secretases, which leads to the release of the neu-
roprotective ectodomain portion of APP (sAPPα) and
prevents Aβ formation. Conversely, the cleavage of APP
by β-secretase or BACE1 leads to the formation of the N-
terminal secreted APPβ (sAPPβ) and an APP C-terminal
fragment (CTF) C99, which is consequently cleaved by
γ-secretase producing Aβ [17-20]. In AD, based on the
prevailing amyloid cascade hypothesis, soluble Aβ peptide
levels are drastically increased, augmenting synaptic dys-
function, calcium dyshomeostasis, inflammation, oxidative
stress as well as tau hyperphosphorylation and the for-
mation of NFTs at specific brain regions in AD [21-23].
Synapses are considered the earliest site of pathology, and
reduced synaptic activity is found to be the best patho-
logical correlate of cognitive impairment in Alzheimer'sdisease [24]. Therefore, it is proposed in the amyloid cas-
cade hypothesis, that accumulation of Aβ is an initial trig-
ger for AD. Recent APP mutation studies support the
notion that increased Aβ production is a major factor
causing AD. These studies identified a potential protective
mutation in APP [25,26]. Substitution of alanine to threo-
nine at position 673 in APP (A673T) was shown to de-
crease the production of Aβ by 50-fold [25]. Individuals
with the mutation A673T on APP have decreased cogni-
tive impairment due to aging and they score better in cog-
nitive tests than those without the mutation. This raises
the possibility that reduced Aβ production throughout an
individual’s lifespan possibly has a protective effect against
AD [25]. The exact molecular mechanisms of how Aβ
accumulation initiates AD are unknown, and a focus has
been set on unraveling the deleterious effects of excess Aβ
on synaptic function. Recent studies have shed light on a
variety of pathways, which Aβ synaptotoxicity is mediated
through.
Despite the well-established foundation of the amyloid
cascade hypothesis, the reported Aβ-targeted trials in AD
patients to date have not been successful [27]. Therefore,
alternative therapeutic approaches focusing on other key
events, such as the hyperphosphorylation and aggregation
of tau have been actively explored. Recent findings show
that the soluble forms of tau are synaptotoxic [28], which
is comparable to that observed with soluble Aβ oligomers
[8,29,30]. Importantly, mislocalized tau in its hyperpho-
sphorylated form has been shown to impair synaptic plas-
ticity before the formation of NFTs [31,32]. However,
failures in Aβ-targeted trials do not dismiss Aβ as a key
initiator in the synaptic dysfunction. Instead, the link be-
tween Aβ and tau is evident as the oligomeric Aβ causes
the mislocalization of tau, leading to synaptic dysfunction
[31,32]. This view is reinforced by findings in a mouse
model with β-amyloid plaque deposition, in which behav-
ioral impairments and excitotoxicity associated with Aβ
are reduced owing to a tau null background [33]. Recent
findings by Ittner et al., also shed light to the possibility
that hyperphosphorylated tau postsynaptically mediates
the Aβ-induced toxicity, further emphasizing the recipro-
cal nature of the tau- and Aβ-mediated deleterious effects
on synapses [32].
Aβ-induced LTD activation via regulation of AMPAR
localization
The processing of APP through the amyloidogenic path-
way is increased in AD, and toxic forms of Aβ accumulate
in the brain. Also, especially in the sporadic, late onset AD
patients, decreased Aβ clearance is centrally associated
with the accumulation of Aβ [34]. Concomitant to the in-
crease in the toxic forms of Aβ, disturbances in signaling
pathways mediated by caspase-3, Wnt, and GSK3β have
been reported [35-38] (Figure 1). Many of these pathways
Figure 1 Schematic representation of specific synaptic alterations induced by excess accumulation of soluble Aβ. Aβ is produced from
APP through sequential cleavages by BACE1 and γ-secretase at the presynaptic site and released to the synaptic cleft. Increased Aβ accumulation
results in the internalization of AMPAR from the postsynaptic membrane, possibly via caspase-3-Akt1-GSK3β or altered LRP6-mediated Wnt
signaling. Aβ may induce activation of extrasynaptic NMDAR (eNMDAR), due to faulty EAAT1/2-mediated regulation of glutamate levels by
astrocytes, leading to the activation induction of downstream RNS/ROS-mediated neurodegenerative events. Additionally, Aβ accumulation
induces tau localization to postsynaptic sites, resulting in the postsynaptic recruitment of Src kinase Fyn. Aβ is also proposed to activate histone
deacetylase 2, resulting in the suppressed expression of genes required for synaptic function and stability, such as BDNF, Cdk5, Homer1, NLGN1,
Syp, GluR1, GluR2, NR2A, NR2B, and STIM2. Abbreviations: Brain-derived neurotrophic factor (BDNF), Cyclin-dependent kinase 5 (CDK5), Homer
homolog 1 (Homer1), Neuroligin 1 (NLGN1), Synaptophysin (Syp), Glutamate receptor 1 (GluR1), Glutamate receptor 2 (GluR2), N-mehtyl-D-Aspartate
2A (NR2A), N-mehtyl-D-Aspartate 2B (NR2B), Stromal interaction molecule 2 (STIM2).
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in the brain with resistance or deficiency of brain insulin
and insulin-like growth factor-1 [39-41]. GSK3β is a well-
known player in AD, strongly associated with the formation
of NFTs via hyperphosphorylation of tau. Recently, GSK3β
has also been linked to AMPAR trafficking and synaptic
plasticity and it is a necessary component for LTD induc-
tion [38] (Figure 1). During the induction of LTD, GSK3β is
activated by protein phosphatase 1 via dephosphorylation
of GSK3β Ser9 [38]. Active GSK3β is known to co-localize
with AMPAR, implying that it regulates the trafficking of
AMPAR from the postsynaptic membrane [38]. On the
other hand, caspase-3 may cleave Akt1, rendering Akt1 in-
capable of inhibiting GSK3β activation [36]. In the presence
of Aβ, caspase-3 is activated and it cleaves Akt1. This
allows the activation of GSK3β by PP1, and possibly the
subsequent removal of AMPARs from the postsynaptic
membrane, resulting in LTD induction [36] (Figure 1).
Aβ-induced synaptic dysfunction can also be mediated
via impairment of the Wnt signaling pathway (Figure 1).
Wnt signaling takes part in the modulation of severalneuronal processes, such as neurotransmitter release at
the presynaptic terminal, glutamate receptor trafficking
and interactions with postsynaptic density protein 95
(PSD-95), which are the key components in LTP and
LTD [42,43]. Recently Liu et al., 2014 [29] focused on
the relationship between Wnt signaling and AD. They
found that low-density lipoprotein receptor-related pro-
tein 6 (LRP6)-mediated Wnt signaling is downregulated
in post-mortem AD brains and that it negatively cor-
relates with Aβ levels. Reduced LRP6-mediated Wnt
signaling may not only lead to synaptic dysfunction, but
also to an increase in the amyloidogenic processing of
APP, creating a vicious cycle between increased produc-
tion of Aβ and decreased LRP6-mediated Wnt signaling
in AD pathogenesis [37]. The exact molecular mecha-
nisms related to synaptic dysfunction due to the de-
crease in LRP6-mediated Wnt signaling is not known,
but it can be hypothesized that LRP6 could be a relevant
factor for the maintenance of glutamate receptors at
the postsynaptic membrane and thus induction of LTP
[37,42,43].
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It has been suggested that LTP disruption in AD could
also be mediated through Aβ-induced overstimulation of
extrasynaptic NMDAR, due to impaired regulation of
glutamate levels (Figure 1). This may lead to calcium
dyshomeostasis and different redox events [7,11,23,44].
In AD, glutamate transporters EAAT1 and EAAT2, which
are responsible for glutamate uptake in glial cells, are
downregulated in the brain of AD patients [43]. This re-
sults in excess accumulation of glutamate to the synaptic
cleft, and overstimulation of NMDAR. Increased Aβ levels
have also been shown to cause astrocyte-mediated glutam-
ate release, which can further exacerbate the excitotoxicity
[11] (Figure 1). Ultimately, overstimulation of NMDAR
triggers various translational and post-translational modi-
fications in a vast set of proteins, resulting in the activa-
tion of downstream pathological events [7,45]. Supporting
the relevance of NMDAR overstimulation in AD, a partial
NMDAR antagonist, which blocks the NMDA overstimu-
lation, has been shown to be neuroprotective in various
animal models and to alleviate both neurodegenerative
and vascular processes [46-48]. Memantine, a partial
NMDAR blocker is also used as a treatment for AD pa-
tients and it has a beneficial impact in Parkinson’s disease
(PD) patients. Unfortunately, memantine only provides
short-term relief, indicating that there are several under-
lying mechanisms contributing to synaptic dysfunction in
these disorders [49-51].
Mislocated tau mediates AD-related synaptic deficiency
Tau has recently been identified as a mediator of
Aβ-related excitotoxicity [32]. Tau is a microtubule-
stabilizing axonal protein, but it is also known to func-
tion in the dendritic compartments with a pivotal role in
postsynaptic plasticity [31,32,52]. At resting-state, tau is
widely spread throughout the dendrites from where it is
transported to postsynaptic sites upon synaptic activation.
Activity-dependent tau translocation simultaneously in-
duces an increase in LTP-related molecular components,
such as PSD-95, glutamate receptor subunit GluR1, and
Fyn, at the postsynaptic site [31]. Moreover, augmented
Aβ levels have been shown to increase the localization of
tau to postsynaptic sites during the resting-state and to
disrupt the recruitment of PSD-95 and GluR1 during syn-
aptic activation [31]. These results collectively suggest that
tau is an important functional constituent sustaining LTP.
This concept is in line with the findings showing Aβ-
related reduction in LTP activation [53]. The abnormal
localization of tau has been especially observed in mice
expressing the full-length P301L mutant of tau [32,54].
Due to the aberrant resting-state localization, tau is likely
able to enhance Aβ-related excitotoxicity by promoting
the localization of the Src kinase Fyn to the postsynaptic
sites [32]. Fyn is responsible for the phosphorylation ofNMDAR subunit 2B (NR2B), which again facilitates the
interaction between NR2B and PSD-95 [55,56]. Disruption
of the NR2B/PSD-95 complex has been shown to prevent
the excitotoxic effects of Aβ, suggesting that tau-dependent
Fyn localization to the postsynaptic site plays a key role
in Aβ-related synaptic dysfunction [32,57]. Furthermore,
the fact that APP23/tau-/- mice show significantly reduced
premature mortality and susceptibility to Aβ-related exci-
totoxicity as compared to APP23 mice provides further
support for the idea that tau mediates Aβ-related excitoxi-
city. Conversely, APP23 mice expressing the full-length
P301L mutant tau show increased premature mortality
[32]. Collectively, these findings highlight tau as a plaus-
ible target for intervention in AD apart from Aβ.
Epigenetic changes in synaptic plasticity-related genes in
Alzheimer’s disease
Other possible pathogenic mechanisms by which Aβ ac-
cumulation may cause synaptic dysfunction in AD are
epigenetic alterations. Recent findings show that Aβ in-
duces epigenetic changes via an increase in histone deace-
tylase 2 (HDAC2) levels, leading to decreased expression
of Arc, BDNF, Cdk5, Erg1, Homer1, NLGN1, Syp, GluR1,
GluR2, Nfl, NR2A, NR2B, STIM2, and Syt1 [58]. These
are essential presynaptic and postsynaptic components
for synaptic plasticity (Figure 1) [6,59-62]. It has been
observed that RNA interference (RNAi)-mediated reduc-
tion of HDAC2 levels in p25 overexpressing mice results
in rescued synaptic morphology and plasticity. The reduc-
tion of HDAC2 in p25 overexpressing mice also results in
the alleviation of cognitive and memory functions [58].
To further prove the relevance of HDAC2 in AD, post-
mortem samples of AD brain were analyzed to show
that HDAC2 accumulation was evident already at early
stages of the disease progression [58]. This further un-
derscores the notion that there are several underlying
mechanisms contributing to synaptic dysfunction in
neurodegenerative diseases.
The above-mentioned factors and pathways are only
some of which may mediate Aβ-induced synaptic dys-
function. Several other factors, which are essential for
synaptic function and possibly affected by Aβ, such as
PSD-95, α7nAChR, PrPc, have also been identified. This
indicates that Aβ may induce synaptic dysfunction in AD
via a very complex combination of different mechanisms
[63-65]. Further studies are needed for a complete under-
standing of the complex array of different pathways regu-
lating synaptic function in health and disease.
Altered synaptic plasticity in Parkinson’s disease
AD-related synaptic dysfunction has been widely studied
as it is clearly connected to neurodegeneration and brain
atrophy in AD patients. However, dysfunction and de-
generation of synapses is a common hallmark of also
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disease (PD), Huntington’s disease (HD), and frontotem-
poral lobar degeneration (FTLD) [66-69]. PD is a progres-
sive, debilitating neurodegenerative disorder characterized
by deterioration of motor capacities, and in some cases,
dementia [70]. The main clinical hallmarks of PD are pro-
gressive loss of substantia nigra pars compacta neurons
and formation of Lewy bodies/neurites in the substantia
nigra, the brain stem and the cerebral cortex. A subset of
PD cases are caused by mutations in genes, such as α-
synuclein, parkin, and LRRK2 [71-73]. A decrease in
LTP activation has been shown in PD models. There is
also evidence that treatment with a dopamine precursor
alleviates the reduced LTP [3,68]. The underlying cause
for the reduced LTP remains elusive, but a relationship
between the above mentioned genetic determinants and
presynaptic function has been suggested. Mutated α-
synuclein, a main component of Lewy bodies found in
post-mortem PD brain, is known to localize to pre-
synaptic terminals and may negatively impact synaptic
vesicle (SV) docking and release [10,74,75]. Burre et al.,
2010 [61] showed that α-synuclein interacts with vesicle-
associated membrane protein 2 (VAMP2), a N-ethylmalei-
mide-sensitive fusion protein receptor (SNARE) complex
protein, and stabilizes the SNARE complex during syn-
aptic activity. This agrees with the findings that muta-
tions in α-synuclein lead to toxic effects and result in
reduced neurotransmitter release in hippocampal pyram-
idal neurons [10]. Furthermore, overexpression of mutated
α-synuclein decreases the levels of synapsin and complexin
2, corroborating the idea that α-synuclein mutations lead to
impaired SV release [10]. Also, co-immunoprecipitation of
Rab 3A and the A30P α-synuclein mutant implicate a link
between SVs and α-synuclein [76,77]. LRRK2, another
important player in PD, has also been hypothesized to
regulate SV recycling, but through endocytic processes
[78-80]. LRRK2 is suggested to colocalize with Rab5b
and thus alter endocytic vesicular transport, suggesting
that LRRK2 may affect SV trafficking [79]. Several find-
ings support the notion that LRRK2 alters endocytosis
and overexpression of LRRK2 has been shown to sup-
press SV endocytosis in mouse primary hippocampal
neurons [80]. These data altogether suggest that defi-
cient synaptic function plays an important role in the
pathogenesis of PD.
Alterations in synaptic activity in Huntington’s disease
and frontotemporal lobar degeneration
Altered synaptic plasticity may also be involved in the
pathogenesis of HD, a neurodegenerative disorder caus-
ing motor dysfunction, psychiatric symptoms, and cogni-
tive decline [81,82]. Evidence shows that impairment of
LTP is evident in HD [2,69]. It has been suggested that
increased glutamate release associated with this diseaseresults in the overexcitement of post-synaptic glutamate
receptors [69]. HD is caused by the expansion of a CAG
repeat in the Htt gene, which leads to the aggregation of
Htt protein to the nucleus and cytoplasm of cells. This
has toxic effects and eventually leads to cell death [82].
The mechanisms by which the Htt mutation causes neu-
rodegeneration remain so far elusive. However, altered
neuronal activity can be initially noticed in the cortex
and striatum of HD brain, from where it further spreads
to other brain areas and leads to neuronal degeneration
[82]. As mentioned above, an increase in glutamate re-
lease is apparent at the early stages of HD, and this
eventually results in the loss of glutamatergic terminals.
A reduction in astrocyte glutamate transporter 1 (GLT1)
levels is commonly observed in HD rodent models,
which could contribute to the accumulation of excess
glutamate [83-85]. Excess glutamate will most likely lead
to stimulation of extrasynaptic NMDAR, leading to the
activation of downstream neurodegenerative events [86].
Supporting this notion, extrasynaptic NMDAR expression
and signaling are increased in acute brain slices and corti-
costriatal cultures from the HD mouse model YAC128.
Moreover, clinical studies have indicated that the partial
NMDAR blocker memantine has beneficial effects in HD
patients [87].
Studies of synaptic alterations in FTLD have been so
far limited. FTLD is heterogeneous group of clinical syn-
dromes, which leads to dementia and primarily affects
the frontal and temporal lobes of the brain [81]. Evi-
dence for synapse loss and a decrease in synaptic density
in FTLD brains implicates that synaptic dysfunction may
also underlie the pathogenesis of this disease entity
[88-90], but no clear explanation for these synaptic alter-
ations have been found. Alterations in synaptic proteins
are also evident at specific layers of the frontal cortex in
FTLD brain, pointing towards the possibility that a
decrease in synaptic activity could underlie the clinical
outcome [67]. In conclusion, eminent data implicate that
altered synaptic function is centrally involved in the early
pathogenesis of the different neurodegenerative diseases.
Although diverse brain regions are specifically affected
in each of these diseases, the current data suggest that
common molecular mechanisms leading to synaptic dys-
function may underlie disease pathogenesis. Therefore,
characterization of factors and pathways, which regulate
synaptic function, is essential and may lead to the discov-
ery of novel therapeutic targets.
The Septin protein family
Alterations in the functions of neuronal cells is evident
in neurodegenerative diseases. Especially, changes in the
synaptic plasticity during early phases of these diseases
have been suggested to lead to the activation of neurode-
generative events. The complexity of the mechanisms of
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these processes are altered in different disorders. How-
ever, understanding the mechanisms leading to deficient
function and degeneration of synapses is essential for a
better comprehension of the pathogenesis of neurode-
generative diseases in general. One of the potential can-
didates regulating synaptic function is the septin protein
family.
Septins are a highly conserved family of GTP-binding
proteins [91,92]. In mammals, there are 13 known septins,
which are divided in to four subgroups; SEPT2 (Septin 1,
2, 4, 5), SEPT3 (Septin 3, 9, 12), SEPT6 (Septin 6, 8, 10,
11, 14), and SEPT7 (Septin 7) [12]. The septin protein
family members are highly expressed in the brain, and are
known to take part in processes such as regulation of
formation, growth and stability of axons and dendrites,
synaptic plasticity, and vesicular trafficking [12,92-96]. In
addition to these physiological functions, septins have
been linked to different neurodegenerative and psychiatric
disorders, such as PD, AD, and schizophrenia [97-99]. The
septins are 30-65-kDa proteins, and they share a common
central GTP-binding domain, 53 highly conserved amino
acids known as the septin unique element (SUE) at the
C-terminus, and a polybasic region located at the imme-
diate N-terminus (Figure 2). The GTP-binding domain
consists of the conserved α-β core, built up by interacting
α-helices and β-strands, and the loop elements, which take
part in the binding of GTP and its possible hydrolysis to
guanosine diphosphate (GDP). The GTP-binding domain
also contains two α-helical elements at the ends of the
conserved core and two insertions, one α-helix and one
β-hairpin, in the GTPase core [100-102]. This domain
mediates the formation of septin filaments and interac-
tions with various other proteins. The neighboring poly-
basic region is believed to assist the GTP-binding
domain in associations with other septins and is capable
of directly binding to the phosphoinositides on the
plasma membrane. The functions of the neighboring
SUE are so far unknown. The rest of the protein is com-
posed of varying N- and C-terminal regions, which may
contain a proline-rich domain and an α-helical coiled-coil
domain, respectively. Many of the septins possess α-
helical extension at their N- and C-termini. The N- and
C-terminal regions also play a vital role in septin interac-
tions [91,103,104].
The role of GTP and GDP in the function and assembly
of septin filaments is still fairly poorly known. Evidence
shows that the presence of GTP regulates the positions
of structural motifs in the GTP-binding domain called
switches. The different conformational changes caused
by the GTP/GDP molecules are believed to be required
for the formation of stable septin complexes and the
dissociation of the complexes during different phases of
the cell cycle [105]. These conformational changes arealso transmitted through to the N-terminal helix affect-
ing the septin-septin interactions. Therefore septins
subgroup SEPT6 (SEPT6, 8, 10, 11, and 14) lack a threo-
nine residue (T78*), which is needed for the hydrolyza-
tion of GTP to GDP [105]. This feature is necessary for
the formation of certain complexes, such as the SEPT2-
6-7 trimeric filament, where GTP can stabilize the
SEPT2-6 GTP-binding domain interaction (G-dimer),
without affecting the SEPT6-7 N- and C-termini inter-
action (NC-dimer) [100] (Figure 2). A further role in the
formation, localization and function of septin complexes
has been hypothesized for GTP and GDP. No direct evi-
dence for this has been found, but mutations in residues
at the GTP-binding site have been shown to alter these
features [101].
Septins in neurodegenerative disease-related synaptic
processes
The septin family provides several interesting candidates
possibly involved in the underlying mechanisms of synap-
tic dysfunction and neurodegeneration in neurodegenera-
tive diseases. Septins have been shown to associate with
AD, PD, HD, FTLD, and Down syndrome [98,99,106-111],
suggesting that septins are involved in the pathogenic
mechanisms of different neurodegenerative diseases. Re-
lated to this, a recent study on the brain proteome
revealed that SEPT2/3 levels were increased, while SEPT5
levels were decreased in the temporal neocortex of
AD patients as compared to non-AD subjects [112].
Also, genetic characterization of SEPT3 gene identified a
polymorphic site at the exon 11, which significantly asso-
ciated with AD in a case-control study [113]. Moreover,
studies in the frontal cortex homogenates of FTLD-U
patients have shown an increase in the truncated forms of
SEPT11 (~45 kDa, ~37 kDa, and ~28 kDa) and the pres-
ence of fibrillar thread-like structures of SEPT11, which
were specifically localized to the superficial cortical layers
[108]. The pathological functions of these thread-like
structures remain elusive, but based on the known lo-
calization of SEPT11 to microtubules and stress fibers, it
can be hypothesized that formation of these structures
could disrupt cytoskeletal functions and result in cellular
toxicity [114,115]. In the context of HD, a significant
down-regulation of SEPT4 was detected in cells express-
ing mutated huntingtin [116].
The diverse interactome of septins suggests that they
have an essential role in vesicle trafficking, which may
be key for e.g. sufficient neurotransmitter release. SEPT8
has been shown to interact with components, such as
VAMP2 and syntaxin-1 of the SNARE complex. SEPT8
possibly promotes the release of VAMP2 from synapto-
physin during action potential stimulation, allowing the
formation of the SNARE complex and subsequently en-
hanced docking of vesicles to the presynaptic membrane
Figure 2 Schematic showing the common structure of septin protein family and the structures of individual septin subgroups. A. The
septin protein structure consists of a GTP-binding domain composed of conserved motifs G1 (GxxxxGK[S/T]), G3 (DxxG) and the GTP-specificity
motif G4 (xKxD). D, G, K, S, and T represent aspartic acid, glycine, lysine, serine, and threonine residues, respectively, and x indicates any amino
acid. The N-terminus consists of a proline-rich domain and a polybasic region. The C-terminus contains a septin unique element (SUE) and a
varying α-helical coiled-coil domain. B. Based on sequence homology and domain composition, the 13 septins have been divided in to four
subgroups (SEPT2, SEPT3, SEPT6, and SEPT7). Septins of subgroup SEPT6 lack a threonine residue (T78*), which is needed for the hydrolyzation of
GTP to GDP. C. The formation of septin filaments mediated by the interaction between GTP-binding domains (G-dimer) and the N- and C-termini
containing faces (NC-dimer). Formation of septin filament structures require different conformational changes mediated by the GTP/GDP molecules,
allowing the assembly and disassembly of stable septin complexes. These conformational changes are also influencing the N-terminal helix and thus
affect the formation of the NC-dimer. Therefore, the lack of a threonine residue (T78*), resulting in the inability of the septin protein to hydrolyze GTP
to GDP, enables the formation of e.g. SEPT2-6-7 complex.
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to negatively regulate SV release at inhibitory presynap-
tic terminals by forming filamentous barricades at the
presynaptic membrane [92]. SEPT5 has also been shown
to interact with syntaxin-1, resulting in decreased exo-
cytosis [117,118] (Figure 3). SEPT5-syntaxin-1 inter-
action and the formation of filamentous barricades is
considered to be regulated by the CDK5-mediated
changes in SEPT5 phosphorylation status [93]. CDK5 is
able to phosphorylate SEPT5 at serine 161 (S161) and327 (S327). Blocking the phosphorylation of SEPT5 at
these sites resulted in enhanced binding of SEPT5 to
syntaxin-1 in PC12 cells [93]. The activity of CDK5 is
deregulated in AD [119]. This could result in altered
SEPT5 phosphorylation and exocytosis at inhibitory
presynaptic terminals, and thus possibly contribute to
altered synaptic activity in AD. Parkin 2 (PARK2), an
E3-ubiquitin ligase, has been identified as another pos-
sible modulator of SEPT5-syntaxin-1 interaction. Interest-
ingly, mutations in PARK2 are responsible for autosomal
Figure 3 The possible roles of septins in synaptic plasticity and mechanisms of neurodegeneration. SEPT4, SEPT5 and SEPT8 have been
hypothesized to control synaptic vesicle trafficking at the presynaptic terminal by interacting with different components of the SNARE complex
and regulating synaptic vesicle localization at the presynaptic membrane. Also SEPT2 and SEPT4 may regulate neurotransmitter levels at the
synapse by regulating glutamate transporter localization in astrocytes. Additionally, SEPT4 may affect caspase-3 activity. SEPT4 functions are
possibly regulated by DYRK1A-mediated phosphorylation. Septins also are known to interact with actin and microtubules, suggesting that they
may affect tau. SEPT1, 2, and 4 have been found to localize in in NFTs.
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PARK2 ubiquitinates SEPT5, which leads to the degrad-
ation of SEPT5, enabling the release of syntaxin-1 to en-
hance SV docking [111]. This agrees with the idea that
PD-associated reduction in parkin results in the accumu-
lation of SEPT5 and subsequent neuronal toxicity in dopa-
minergic neurons [107,120].
The fact that SEPT1, 2, and 4 have been found in
NFTs provides further confirmation that different septin
family members are associated with neurological diseases
[98,110]. SEPT2 is involved in synaptic plasticity and has
been found to interact with the glutamate transporter
EAAT1 and regulate its cellular localization (Figure 3).
SEPT2 binding to EAAT1 is GDP-dependent and GDP-
bound SEPT2 is capable of binding to and internalizing
EAAT1. GDP binding to septins is considered to disrupt
the formation of septin filaments and thus it is hypothe-
sized that the GTP-bound form of SEPT2 is capable of
forming septin filaments and stabilizing EAAT1 at the
cell surface [100,121]. The absence of EAAT1 from the
cell surface could lead to the increased levels of glutamate
in the extracellular space and possibly overstimulation of
NMDAR [121] (Figure 3). Co-immunoprecipitation stud-
ies of SEPT2 and EAAT1 have revealed that also SEPT4
interacts with EAAT1, which points to a possible for-
mation of heteromeric complexes between SEPT2 andSEPT4 [121]. In addition to the co-localization with NFTs
and EAAT1, SEPT4 has been linked to PD and Down syn-
drome through interaction with parkin and DYRK1A
(dual-specificity tyrosine phosphorylation-regulated kinase
1A) [106,122]. DYRK1A levels are known to be increased
in Down syndrome patients and it has been shown to
phosphorylate SEPT4 at S68 and S107. The direct impact
of this phosphorylation is elusive, but DYRK1A also
phosphorylates α-synuclein, which is another interact-
ing partner of SEPT4 [122]. Since α-synuclein is the key
component of PD-related Lewy bodies, the DYRK1A-
mediated phosphorylation of SEPT4 may be associated
with the formation of Lewy bodies [109,122]. Loss of
SEPT4 in dopaminergic neurons has been observed in
the sporadic PD patients, which could be due to the
sequestration of SEPT4 into α-synuclein aggregates and
neuronal loss [109,123]. The loss of SEPT4 also results
in diminished dopaminergic neurotransmission, sugges-
ting that SEPT4 may play a central role in dopamine
release and reuptake in the presynaptic machinery [109].
SEPT4, similarly to SEPT5, is also a substrate for parkin,
emphasizing further the potential importance of SEPT4 in
the pathogenesis of PD [106]. Furthermore, SEPT4 may
be involved in AD based on its interactions with X-linked
inhibitor of apoptosis protein, a regulator of caspase-3
activity [124,125] (Figure 3).
Marttinen et al. Molecular Neurodegeneration  (2015) 10:16 Page 9 of 12Overall, considering the localization of septins in neu-
rons, their involvement in the regulation of synaptic func-
tions, and their other known interactions, septins may
prove as central candidates involved in the pathogenic
mechanisms of various neurological diseases. However,
further studies are need to comprehensively understand
septin functions and the outcomes of septin interactions.
A focus should also be set on understanding the effects of
septin-septin interactions, because they are known to form
various hetero- and homomeric structures, which have
regulatory and compensatory effects on neuronal func-
tions [104]. Recent findings by Tokhtaeva et al. further
emphasize the importance of studying septin-septin in-
teractions, since disabling the formation of heteromeric
septin oligomers impairs the exocytosis of proteins and
neurotransmitters [126]. It was also shown that septins
undergo constant reassembly at different phases of vesicle
recycling, supporting their role in the various steps related
to neurotransmitter release and uptake [126].
Conclusion
The underlying mechanisms in different neurodegenera-
tive disorders have remained elusive. However, increas-
ing evidence suggests that abnormal synaptic activity
and synaptic dysfunction are common in different neu-
rodegenerative diseases and may in fact represent some
of the earliest pathogenic alterations during their patho-
genesis. In agreement with this notion, recent studies
have shown that changes in the expression levels of spe-
cific synaptic proteins in the cerebrospinal fluid reflect
degeneration of synapses and can be successfully used to
predict AD patients and evaluate MCI-to-AD conversion
at very early stages of the disease [127,128]. The observa-
tion that the protein levels of different septins are altered
in AD patients [114] suggests that also septins could rep-
resent early markers linked to synaptic dysfunction and
synaptoxicity. Alterations in the expression levels, phos-
phorylation status, and subcellular localization of various
pre- and postsynaptic proteins in neurodegenerative dis-
eases emphasize that extremely complex mechanisms are
likely to be involved in the etiology of these diseases.
Therefore, further research is needed to unravel the spe-
cific mechanisms by which synaptic plasticity is affected
in neurodegenerative diseases. Thus, it is plausible that
novel disease biomarkers and therapeutic targets will be
identified through more detailed characterization of the
aberrant changes in synaptic plasticity-related factors
and pathways at different phases during the progression
of these diseases [129]. This may require identification
of new candidates, which are involved in the regulation
of synaptic plasticity and neurodegenerative disease-
related mechanisms. Septin protein family, implicated in
the regulation of several different aspects of synaptic
vesicle trafficking and neurotransmitter release, mayoffer such novel candidates for further assessments in
the pathogenesis of neurodegenerative diseases. Therefore,
the future studies should focus on better understanding
of the functions, regulation, and interactomes of different
septin family members in health and disease.
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